203 related articles for article (PubMed ID: 1707655)
1. Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces.
Busch R; Strang G; Howland K; Rothbard JB
Int Immunol; 1990; 2(5):443-51. PubMed ID: 1707655
[TBL] [Abstract][Full Text] [Related]
2. Effect of natural polymorphism at residue 86 of the HLA-DR beta chain on peptide binding.
Busch R; Hill CM; Hayball JD; Lamb JR; Rothbard JB
J Immunol; 1991 Aug; 147(4):1292-8. PubMed ID: 1869824
[TBL] [Abstract][Full Text] [Related]
3. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens.
Zhu X; Bavari S; Ulrich R; Sadegh-Nasseri S; Ferrone S; McHugh L; Mage M
Eur J Immunol; 1997 Aug; 27(8):1933-41. PubMed ID: 9295029
[TBL] [Abstract][Full Text] [Related]
4. Peptides recognized by class I restricted T cells also bind to MHC class II molecules.
Hickling JK; Fenton CM; Howland K; Marsh SG; Rothbard JB
Int Immunol; 1990; 2(5):435-41. PubMed ID: 2085488
[TBL] [Abstract][Full Text] [Related]
5. Masking of a cathepsin G cleavage site in vivo contributes to the proteolytic resistance of major histocompatibility complex class II molecules.
Burster T; Macmillan H; Hou T; Schilling J; Truong P; Boehm BO; Zou F; Lau K; Strohman M; Schaffert S; Busch R; Mellins ED
Immunology; 2010 Jul; 130(3):436-46. PubMed ID: 20331476
[TBL] [Abstract][Full Text] [Related]
6. Properties of HLA class II molecules divergently associated with Goodpasture's disease.
Phelps RG; Jones V; Turner AN; Rees AJ
Int Immunol; 2000 Aug; 12(8):1135-43. PubMed ID: 10917888
[TBL] [Abstract][Full Text] [Related]
7. Antigen presentation mediated by recycling of surface HLA-DR molecules.
Pinet V; Vergelli M; Martin R; Bakke O; Long EO
Nature; 1995 Jun; 375(6532):603-6. PubMed ID: 7540726
[TBL] [Abstract][Full Text] [Related]
8. Conformational and structural characteristics of peptides binding to HLA-DR molecules.
Hill CM; Hayball JD; Allison AA; Rothbard JB
J Immunol; 1991 Jul; 147(1):189-97. PubMed ID: 1711073
[TBL] [Abstract][Full Text] [Related]
9. Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding.
Jardetzky TS; Gorga JC; Busch R; Rothbard J; Strominger JL; Wiley DC
EMBO J; 1990 Jun; 9(6):1797-803. PubMed ID: 2189723
[TBL] [Abstract][Full Text] [Related]
10. Molecular mimicry by major histocompatibility complex molecules and peptides accounts for some alloresponses.
Lechler RI; Heaton T; Barber L; Bal V; Batchelor JR; Lombardi G
Immunol Lett; 1992 Sep; 34(1):63-9. PubMed ID: 1478706
[TBL] [Abstract][Full Text] [Related]
11. Interactions between immunogenic peptides and HLA-DR molecules.
Rothbard JB; Busch R
Immunol Res; 1990; 9(3):178-89. PubMed ID: 2230404
[No Abstract] [Full Text] [Related]
12. Presentation of cytosolic antigen by HLA-DR requires a function encoded in the class II region of the MHC.
Malnati MS; Ceman S; Weston M; DeMars R; Long EO
J Immunol; 1993 Dec; 151(12):6751-6. PubMed ID: 8258689
[TBL] [Abstract][Full Text] [Related]
13. Two processing pathways for the MHC class II-restricted presentation of exogenous influenza virus antigen.
Pinet V; Malnati MS; Long EO
J Immunol; 1994 May; 152(10):4852-60. PubMed ID: 8176208
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of major histocompatibility complex class II gene expression and demonstration of antigen-specific T cell response indicate a new phenotype in class II-deficient patients.
Hauber I; Gulle H; Wolf HM; Maris M; Eggenbauer H; Eibl MM
J Exp Med; 1995 Apr; 181(4):1411-23. PubMed ID: 7699327
[TBL] [Abstract][Full Text] [Related]
15. Identification of HLA-DR1 beta chain residues critical for binding staphylococcal enterotoxins A and E.
Karp DR; Long EO
J Exp Med; 1992 Feb; 175(2):415-24. PubMed ID: 1370684
[TBL] [Abstract][Full Text] [Related]
16. Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding.
Roche PA; Cresswell P
Nature; 1990 Jun; 345(6276):615-8. PubMed ID: 2190094
[TBL] [Abstract][Full Text] [Related]
17. Implication of HLA-DR residues at positions 67, 71, and 86 in interaction between HLA-DR11 and peptide HA306-320.
Zeliszewski D; Golvano JJ; Gaudebout P; Dorval I; Freidel C; Gebuhrer L; Betuel H; Borras-Cuesta F; Sterkers G
J Immunol; 1993 Dec; 151(11):6237-47. PubMed ID: 7504016
[TBL] [Abstract][Full Text] [Related]
18. High-affinity binding of an influenza hemagglutinin-derived peptide to purified HLA-DR.
Roche PA; Cresswell P
J Immunol; 1990 Mar; 144(5):1849-56. PubMed ID: 2307844
[TBL] [Abstract][Full Text] [Related]
19. Binding of labelled influenza matrix peptide to HLA DR in living B lymphoid cells.
Ceppellini R; Frumento G; Ferrara GB; Tosi R; Chersi A; Pernis B
Nature; 1989 Jun; 339(6223):392-4. PubMed ID: 2786148
[TBL] [Abstract][Full Text] [Related]
20. Functional interaction between human histocompatibility leukocyte antigen (HLA) class II and mouse CD4 molecule in antigen recognition by T cells in HLA-DR and DQ transgenic mice.
Yamamoto K; Fukui Y; Esaki Y; Inamitsu T; Sudo T; Yamane K; Kamikawaji N; Kimura A; Sasazuki T
J Exp Med; 1994 Jul; 180(1):165-71. PubMed ID: 8006580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
